Loading, Please Wait...
SAN DIEGO, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its audited financial results for the fourth quarter and full year ended December 31, 2018.
Key Accomplishments in 2018:
Fourth Quarter 2018 Results:
The Company reported revenue of $2.0 million for the fourth quarter of 2018, compared to $3.7 million for the fourth quarter of 2017. U.S. revenue of $0.8 million represented 41% of revenue as compared to $2.9 million and 77% of revenue in the fourth quarter of 2017. International revenue of $1.2 million represented 59% of revenue in the fourth quarter of 2018, compared to $0.8 million and 23% of revenue in the fourth quarter of 2017.
Cost of goods sold was $1.5 million during the three months ended December 31, 2018, down from $1.7 million for the prior-year comparable period. Gross profit for the fourth quarter of 2018 was $0.5 million, resulting in a gross margin of 26%, compared to a gross profit of $2.0 million and gross margin of 54% for the fourth quarter of 2017.
Research and development expense for the fourth quarter of 2018 totaled $2.3 million, down from $2.7 million in the fourth quarter of 2017. Selling, general and administrative expense decreased to $6.9 million for the fourth quarter of 2018, compared to $9.2 million in the fourth quarter of 2017.
Operating loss for the fourth quarter of 2018 was $8.7 million, compared to an operating loss of $9.9 million for the fourth quarter of 2017.
Net loss in the fourth quarter of 2018 was $8.8 million, compared to a net loss of $10.1 million in the fourth quarter of 2017. The net loss per share was $0.39 for the fourth quarter of 2018 as compared to the net loss per share of $0.60 for the fourth quarter of 2017.
As of December 31, 2018, Obalon had cash, cash equivalents and short-term investments of $23.7 million and total debt of $10.0 million. During the first quarter of 2019, the Company subsequently drew down the remaining $10.0 million available under its term loan, for total debt outstanding of $20.0 million.
Full Year 2018 Results
Obalon reported full year 2018 revenue of $9.1 million, as compared to $9.9 million for the full year 2017. U.S. revenue of $4.7 million represented 52% of full year 2018 revenue, decreasing from $8.3 million or 83% of full year 2017 revenue. International revenue of $4.4 million in 2018 equated to 48% of full year 2018 revenue as compared to $1.6 million of international revenue in 2017 which equated to 17% of full year 2017 revenue.
Gross profit for the full year 2018 was $3.7 million, resulting in a gross margin of 40%, as compared to $5.1 million for the full year 2017 and a gross margin of 51%.
Research and development expense totaled $10.7 million for the full year 2018, as compared to $10.6 million for the full year 2017. Selling, general and administrative expense increased to $29.9 million for the full year 2018, as compared to $28.8 million for the full year 2017.
Operating loss for the full year 2018 was $37.0 million, compared to an operating loss of $34.4 million for the full year 2017.
Net loss was reported at $37.4 million for the full year 2018 compared to a net loss of $34.8 million for the full year 2017. The net loss per share was $1.96 for the full year 2018, as compared to the net loss per share of $2.08 for the full year 2017.
A conference call to discuss fourth quarter and full year 2018 financial results is scheduled for today, February 22, 2019, at 8:30 AM Eastern Time (5:30 AM Pacific Time). Interested parties may access the conference call by dialing (844) 889-7791 (U.S.) or (661) 378-9934 (international) using passcode 4889307. Media and individuals will be in a listen-only mode. Participants are asked to dial in a few minutes prior to the call to register for the event. The conference call will also be webcast live at: http://edge.media-server.com/m6/p/58t82ok5
An archive of the webcast will be available for twelve months following the event on the Obalon Therapeutics, Inc. website located at http://investor.obalon.com in the “News & Events” section.
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements that are not purely historical regarding Obalon’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to new products and their potential benefits. All forward-looking statements and reasons why results might differ included in this press release are made as of the date of this release, based on information currently available to Obalon, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward looking statements. The risks and uncertainties that may cause actual results to differ materially from Obalon’s current expectations are more fully described in Obalon’s annual report on Form 10-K for the period ended December 31, 2018, as filed with the Securities and Exchange Commission on February 22, 2019, and its other reports, each as filed with the Securities and Exchange Commission. Except as required by law, Obalon assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. For more information, please visit www.obalon.com.
For Obalon Therapeutics, Inc.Investor Contact:
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
|OBALON THERAPEUTICS, INC.|
|CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS|
|(in thousands, except shares and per share data)|
Three Months Ended
|Year Ended December 31,|
|Cost of revenue||1,504||1,702||5,423||4,829|
|Research and development||2,338||2,689||10,697||10,647|
|Selling, general and administrative||6,854||9,223||29,946||28,829|
|Total operating expenses||9,192||11,912||40,643||39,476|
|Loss from operations||(8,660||)||(9,922||)||(36,965||)||(34,391||)|
|Interest expense, net||(62||)||(25||)||(226||)||(135||)|
|Other comprehensive income (loss)||2||—||5||(4||)|
|Total comprehensive loss||$||(8,754||)||$||(10,120||)||$||(37,375||)||$||(34,769||)|
|Net loss per share, basic and diluted||$||(0.39||)||$||(0.60||)||$||(1.96||)||$||(2.08||)|
|Weighted-average common shares outstanding, basic and diluted||22,595,768||16,918,702||19,036,693||16,717,106|
|OBALON THERAPEUTICS, INC.|
|CONSOLIDATED BALANCE SHEETS|
|(in thousands, except shares and par value data)|
|Cash and cash equivalents||$||21,187||$||21,108|
|Accounts receivable, net||870||4,223|
|Other current assets||2,462||1,714|
|Total current assets||28,647||51,755|
|Property and equipment, net||1,739||1,346|
|Liabilities and Stockholders’ Equity|
|Other current liabilities||1,985||1,773|
|Current portion of long-term loan||9,930||1,958|
|Total current liabilities||17,231||10,011|
|Long-term loan, excluding current potion||—||7,964|
|Total long-term liabilities||48||7,977|
|Commitments and contingencies|
|Common stock, $0.001 par value; 100,000,000 and 300,000,000 shares authorized at December 31, 2018 and December 31, 2017, respectively; 23,513,292 and 17,500,604 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively||23||18|
|Additional paid-in capital||161,838||146,474|
|Accumulated other comprehensive loss||—||(5||)|
|Total stockholders’ equity||13,107||35,113|
|Total liabilities and stockholders’ equity||$||30,386||$||53,101|
|OBALON THERAPEUTICS, INC.|
|CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS|
|Year Ended December 31,|
|Adjustments to reconcile net loss to net cash used in operating activities:|
|Fair value of stock issued for legal settlement||—||1,606|
|Loss on disposal of fixed assets||107||—|
|(Accretion) amortization of investment (discount) premium, net||(50||)||18|
|Amortization of debt discount||37||42|
|Change in operating assets and liabilities:|
|Accounts receivable, net||3,353||(4,223||)|
|Accounts receivable from related party||—||515|
|Other current assets||98||(470||)|
|Other current and long term liabilities||68||663|
|Net cash used in operating activities||(29,432||)||(30,624||)|
|Purchases of short-term investments||(9,102||)||(94,613||)|
|Maturities of short-term investments||29,901||73,800|
|Purchase of property and equipment||(1,282||)||(1,043||)|
|Net cash provided by (used in) investing activities||19,517||(21,856||)|
|Proceeds from issuance of common stock, net of issuance costs||9,823||—|
|Fees paid in connection with loan amendment||(30||)||—|
|Proceeds from stock issued under employee stock purchase plan||148||429|
|Proceeds from sale of common stock upon exercise of stock options||53||184|
|Net cash provided by financing activities||9,994||613|
|Net increase (decrease) in cash and cash equivalents||79||(51,867||)|
|Cash and cash equivalents at beginning of period||21,108||72,975|
|Cash and cash equivalents at end of period||$||21,187||$||21,108|
|Supplemental cash flow information:|
|Income taxes paid||$||7||$||2|
|Property and equipment in accounts payable||$||201||$||83|
|Fair value of commitment shares issued||$||595||$||—|
|Unpaid issuance costs||$||250||$||—|